ICON to Create Translational Medicine Unit in UK

Monday, December 21, 2009 07:53 AM

Dublin-based contract research organization (CRO) ICON is preparing to open a new hospital-based translational medicine unit in the UK—the result of a partnership with the Central Manchester University Hospitals Foundation (CMFT).

Under the terms of the agreement, signed last summer, ICON will create translational medicine facilities on the newly developed Manchester Royal Infirmary (MRI) campus. The exclusive agreement, which runs until 2012, will help ICON meet increasing demand for hospital-based first-in-human studies.

The new unit—the first deliverable from the ICON-CMFT collaboration—will open in April, and will include 34 beds, an onsite Good Manufacturing Practices pharmacy, a sample handling laboratory and administrative space. It will be connected to MRI’s Accident and Emergency Department.  The unit will also offer environmentally controlled pharmacodynamic study testing suites.

ICON will develop an additional facility on the MRI campus.

The CRO would not comment on the size of its translational medicine business but said translational research is a growth area.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 2

Roche's $8.3B InterMune buy continues its buying spree with 'bolt-on' deal, fueling record M&A activity

FDA action plan seeks to close gap in women and minority patient representation in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs